Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
06:00pm, Thursday, 21'st May 2026
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase
Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)
09:00am, Wednesday, 20'th May 2026
Biogen stock fell approximately 6.4% in a single session after Phase 2 "CELIA" trial data for diranersen failed to meet its primary endpoint. NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NA
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud
04:00pm, Tuesday, 19'th May 2026
NEW YORK--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) shareholders lost approximately 6.4% of their investment value on May 14, 2026, when the company disclosed that its Phase 2 "CELIA" trial for Alzh
BIIB ALERT: Levi & Korsinsky Investigates Biogen Inc. for Possible Securities Fraud Violations
09:50am, Monday, 18'th May 2026
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ:BIIB) concerning potential vio
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
09:00am, Monday, 18'th May 2026
Biogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint. NEW YORK, May 18, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) shareholder
Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)
07:02pm, Friday, 15'th May 2026
Biogen shares dropped 6.4% after Phase 2 CELIA trial data revealed information absent from the Company's filings. NEW YORK, May 15, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) investors lost appro
Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details
03:34pm, Friday, 15'th May 2026
New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ: BIIB) concerning potential vi
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
12:31pm, Friday, 15'th May 2026
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity
11:10am, Friday, 15'th May 2026
Biogen Inc. is upgraded from Sell to Hold, reflecting recent strategic moves and a modest rebound despite persistent structural challenges. BIIB's acquisition of Apellis for ~$5.6bn adds near-term rev
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
07:10pm, Thursday, 14'th May 2026
Biogen NASDAQ: BIIB is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company's next phase of growth, Adam
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
12:10pm, Thursday, 14'th May 2026
Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move it into Phase 3 t
Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.
09:07am, Thursday, 14'th May 2026
Biogen's diranersen showed ‘robust reductions' in key biomarkers during a Phase 2 trial, the biotech said.
Biogen Completes Acquisition of Apellis Pharmaceuticals
08:35am, Thursday, 14'th May 2026
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a l
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating dirane
Biogen's Alzheimer's drug fails to meet mid-stage trial goal
07:03am, Thursday, 14'th May 2026
Biogen said on Thursday its Alzheimer's drug did not meet the main goal of a mid-stage trial.
